Literature DB >> 1325102

Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.

E Pelosi1, K A Hicks, S L Sacks, D M Coen.   

Abstract

Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance. Acyclovir-resistance can be due either to mutations in the viral thymidine kinase gene or in the viral DNA polymerase gene. Although clinical resistance has most frequently been associated with thymidine kinase alterations, heterogeneity in clinical isolates has not been addressed frequently. The potential for such heterogeneity has been emphasized by a report describing a pathogenic clinical isolate containing within its population at least one thymidine kinase-proficient DNA polymerase mutant as well as mutants exhibiting thymidine kinase-deficiency (Sacks, et al., 1989). We provide here additional characterization of this isolate and speculations regarding its significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325102     DOI: 10.1007/978-1-4615-3462-4_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.

Authors:  F C Spector; L Liang; H Giordano; M Sivaraja; M G Peterson
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

2.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 3.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.